Abstract 41P
Background
The importance of regulating and improving the tumor immune microenvironment is increasingly being recognized. While it has been reported that therapeutic agents for hyperlipidemia, in particular statins, can induce cancer cell growth suppression and anti-metastatic effects in breast cancer, few studies have investigated the correlation between improvement of lipid metabolism and antitumor immune response and cancer prognosis in vivo.
Methods
Except for patients with ductal carcinoma in situ, 938 breast cancer patients treated with curative surgery were examined. The correlation between serum levels of total-cholesterol and triglyceride, and clinicopathological features, including pre- and postoperative neutrophil-to-lymphocyte ratio (NLR) and tumor-infiltrating lymphocytes (TILs), and prognosis was evaluated retrospectively.
Results
194 patients were receiving treatment for hyperlipidemia. Recurrence-free survival (RFS) and overall survival (OS) did not differ significantly between users of the drug for hyperlipidemia or non-users (p = 0.782, log-rank) (p = 0.304, log-rank). Among postmenopausal patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, who were treated for hyperlipidemia, the group with good serum lipid control had significantly better RFS (p = 0.014, log-rank). Good serum lipid control was also significantly correlated with low postoperative NLR (p = 0.024). In addition, high-TILs in resected tissues was significantly associated with preoperative serum lipid levels (p = 0.039). In the drug type, lipophilic statin users had lower recurrence rate than hydrophilic statin users (8.2 % vs 16.0 %).
Conclusions
Good control of serum lipid metabolism may have a relationship with improvement of tumor immune microenvironment and favorable outcome in postmenopausal HR-positive/HER2-negative breast cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract